Table 2.
Association Between IQGAP3, PIK3C2B Expression and Clinicopathological Factors
| Variables | IQGAP3 | PIK3C2B | ||||
|---|---|---|---|---|---|---|
| Negative | Positive | t/χ2, P-value | Negative | Positive | t/χ2, P-value | |
| Age, years | 0.249, 0.618 | 0.013, 0.909 | ||||
| ≤60 | 25(49.0%) | 37(53.6%) | 22(52.4%) | 40(51.3%) | ||
| >60 | 26(51.0%) | 32(46.4%) | 20(47.6%) | 38(48.7%) | ||
| Sex | 0.260, 0.610 | 0.155, 0.694 | ||||
| Male | 34(66.7%) | 49(71.0%) | 30(71.4%) | 53(67.9%) | ||
| Female | 17(33.3%) | 20(29.0%) | 12(28.6%) | 25(32.1%) | ||
| Location | 0.198, 0.906 | 1.767, 0.413 | ||||
| Left | 8(15.7%) | 10(14.5%) | 4(9.5%) | 14(17.9%) | ||
| Right | 17(33.3%) | 21(30.4%) | 13(31.0%) | 25(32.1%) | ||
| Transverse | 26(51.0%) | 38(55.1%) | 25(59.5%) | 39(50.0%) | ||
| Tumor size (cm) | 0.612, 0.434 | 0.006, 0.938 | ||||
| <5 | 31(60.8%) | 37(53.6%) | 24(57.1%) | 44(56.4%) | ||
| ≥5 | 20(39.2%) | 32(46.4%) | 18(42.9%) | 34(43.6%) | ||
| Differentiation | 7.151, 0.028 | 3.070, 0.215 | ||||
| Well | 6(11.8%) | 2(2.9%) | 5(11.9%) | 3(3.8%) | ||
| Moderate | 19(37.3%) | 17(24.6%) | 13(31.0%) | 23(29.5%) | ||
| Poor | 26(51.0%) | 50(72.5%) | 24(57.1%) | 52(66.7%) | ||
| Invasion depth | 4.940, 0.176 | 2.363, 0.501 | ||||
| T1 | 3(5.9%) | 0(0.0%) | 0(0.0%) | 3(3.8%) | ||
| T2 | 11(21.6%) | 12(17.4%) | 8(19.0%) | 15(19.2%) | ||
| T3 | 29(56.9%) | 47(68.1%) | 29(69.0%) | 47(60.3%) | ||
| T4 | 8(15.7%) | 10(14.5%) | 5(11.9%) | 13(16.7%) | ||
| Lymph node metastasis stages | 9.123, 0.010 | 0.725, 0.696 | ||||
| N0 | 15(29.4%) | 6(8.7%) | 9(21.4%) | 12(15.4%) | ||
| N1 | 5(9.8%) | 12(17.4%) | 6(14.3%) | 11(14.1%) | ||
| N2 | 31(60.8%) | 51(73.9%) | 27(64.3%) | 55(70.5%) | ||
| TNM stages | 13.606, 0.003 | 8.749, 0.033 | ||||
| I | 6(11.8%) | 0(0.0%) | 1(2.4%) | 5(6.4%) | ||
| II | 9(17.6%) | 6(8.7%) | 8(19.0%) | 7(9.0%) | ||
| III | 28(54.9%) | 56(81.2%) | 32(76.2%) | 52(66.7%) | ||
| IV | 8(15.7%) | 7(10.1%) | 1(2.4%) | 14(17.9%) | ||
| TNM stages 2 | 8.717, 0.003 | 0.691, 0.406 | ||||
| I+II | 15(29.4%) | 6(8.7%) | 9(21.4%) | 12(15.4%) | ||
| III+IV | 36(70.6%) | 63(91.3%) | 33(78.6%) | 66(84.6%) | ||
| Lymphatic invasion | 3.173, 0.075 | 5.199, 0.023 | ||||
| No | 22(43.1%) | 19(27.5%) | 20(47.6%) | 21(26.9%) | ||
| Yes | 29(56.9%) | 50(72.5%) | 22(52.4%) | 57(73.1%) | ||
| Vessel invasion | 4.125, 0.042 | 9.111, 0.003 | ||||
| No | 24(47.1%) | 20(29.0%) | 23(54.8%) | 21(26.9%) | ||
| Yes | 27(52.9%) | 49(71.0%) | 19(45.2%) | 57(73.1%) | ||
| Distant metastasis | 0.823, 0.364 | 6.049, 0.014 | ||||
| No | 43(84.3%) | 62(89.9%) | 41(97.6%) | 64(82.1%) | ||
| Yes | 8(15.7%) | 7(10.1%) | 1(2.4%) | 14(17.9%) | ||
| PIK3C2B expression | 5.669, 0.017 | |||||
| Negative | 24(47.1%) | 18(26.1%) | ||||
| Positive | 27(52.9%) | 51(73.9%) | ||||
Notes: The pathological staging follows to the WHO’s (2010) pathological classification of CRC; Invasion Depth (T Grade) grade T1a and T1b are classed as T1, T4a and T4b are classed as T4; Lymphatic Metastasis (N Grade) grade N1 includes N1a, N3b and N3c; TNM grade IIa, IIb and IIc are classed as TNM grade II, IIIa, IIIb and IIIc are classed as TNM grade III, includes IVa and IVb are classed as grade IV.